A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG.

Danny Rischin,Daniela Matei,Jeffrey C. Goh,Michelle Vaughan,Philip Beale,Meaghan Tenney,J Martyn,Dirkje Willemien Sommeijer,Jose Iglesias,David C. Bibby,Jeremy Simpson,Elizabeth E. Doolin,Corinne E. Williams,Martin R. Stockler

A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG.

2013

Danny Rischin
Daniela Matei
Jeffrey C. Goh
Michelle Vaughan
Philip Beale
Meaghan Tenney
J Martyn
Dirkje Willemien Sommeijer
Jose Iglesias
David C. Bibby
Jeremy Simpson
Elizabeth E. Doolin
Corinne E. Williams
Martin R. Stockler

TPS5612 Background: BNC105P is a tubulin polymerization inhibitor and a vascular disrupting agent (VDA). In vivo exposure to BNC105P leads to selective damage of tumor vasculature in both primary a...

Keywords:

Oncology
Carboplatin
Ovarian cancer
Vascular Disrupting Agent BNC105P
Pathology
Internal medicine
Gemcitabine
Medicine
platinum sensitive
In vivo
collaborative group
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations